Logo image of PACB

PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Fundamental Analysis

USA - NASDAQ:PACB - US69404D1081 - Common Stock

1.42 USD
-0.11 (-7.19%)
Last: 10/10/2025, 8:50:25 PM
1.41 USD
-0.01 (-0.7%)
After Hours: 10/10/2025, 8:50:25 PM
Fundamental Rating

2

Taking everything into account, PACB scores 2 out of 10 in our fundamental rating. PACB was compared to 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of PACB have multiple concerns. PACB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PACB had negative earnings in the past year.
PACB had a negative operating cash flow in the past year.
PACB had negative earnings in 4 of the past 5 years.
PACB had negative operating cash flow in 4 of the past 5 years.
PACB Yearly Net Income VS EBIT VS OCF VS FCFPACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -63.76%, PACB is doing worse than 87.50% of the companies in the same industry.
PACB has a worse Return On Equity (-856.02%) than 92.86% of its industry peers.
Industry RankSector Rank
ROA -63.76%
ROE -856.02%
ROIC N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
PACB Yearly ROA, ROE, ROICPACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With a Gross Margin value of 24.00%, PACB is not doing good in the industry: 78.57% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of PACB has declined.
PACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
PACB Yearly Profit, Operating, Gross MarginsPACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PACB has more shares outstanding
Compared to 5 years ago, PACB has more shares outstanding
The debt/assets ratio for PACB is higher compared to a year ago.
PACB Yearly Shares OutstandingPACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
PACB Yearly Total Debt VS Total AssetsPACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -5.58, we must say that PACB is in the distress zone and has some risk of bankruptcy.
PACB has a worse Altman-Z score (-5.58) than 87.50% of its industry peers.
PACB has a Debt/Equity ratio of 10.51. This is a high value indicating a heavy dependency on external financing.
PACB has a worse Debt to Equity ratio (10.51) than 94.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.51
Debt/FCF N/A
Altman-Z -5.58
ROIC/WACCN/A
WACC6.55%
PACB Yearly LT Debt VS Equity VS FCFPACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 6.92 indicates that PACB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.92, PACB belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
PACB has a Quick Ratio of 6.02. This indicates that PACB is financially healthy and has no problem in meeting its short term obligations.
PACB has a better Quick ratio (6.02) than 85.71% of its industry peers.
Industry RankSector Rank
Current Ratio 6.92
Quick Ratio 6.02
PACB Yearly Current Assets VS Current LiabilitesPACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

PACB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -52.67%.
Looking at the last year, PACB shows a very negative growth in Revenue. The Revenue has decreased by -17.35% in the last year.
The Revenue has been growing by 11.12% on average over the past years. This is quite good.
EPS 1Y (TTM)-52.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.13%
Revenue 1Y (TTM)-17.35%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%10.42%

3.2 Future

The Earnings Per Share is expected to grow by 12.41% on average over the next years. This is quite good.
The Revenue is expected to grow by 14.38% on average over the next years. This is quite good.
EPS Next Y-4.67%
EPS Next 2Y29.4%
EPS Next 3Y20.27%
EPS Next 5Y12.41%
Revenue Next Year3.51%
Revenue Next 2Y9.4%
Revenue Next 3Y13.3%
Revenue Next 5Y14.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PACB Yearly Revenue VS EstimatesPACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
PACB Yearly EPS VS EstimatesPACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PACB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PACB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PACB Price Earnings VS Forward Price EarningsPACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PACB Per share dataPACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PACB's earnings are expected to grow with 20.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.4%
EPS Next 3Y20.27%

More info and screens

0

5. Dividend

5.1 Amount

PACB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (10/10/2025, 8:50:25 PM)

After market: 1.41 -0.01 (-0.7%)

1.42

-0.11 (-7.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners57.25%
Inst Owner Change0%
Ins Owners0.98%
Ins Owner Change-0.28%
Market Cap426.53M
Analysts76.67
Price Target2.04 (43.66%)
Short Float %16.69%
Short Ratio6.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-313.85%
Min EPS beat(2)-646.96%
Max EPS beat(2)19.26%
EPS beat(4)2
Avg EPS beat(4)-189.42%
Min EPS beat(4)-646.96%
Max EPS beat(4)19.26%
EPS beat(8)3
Avg EPS beat(8)-114.36%
EPS beat(12)4
Avg EPS beat(12)-75.63%
EPS beat(16)5
Avg EPS beat(16)-58.32%
Revenue beat(2)2
Avg Revenue beat(2)4.48%
Min Revenue beat(2)3.35%
Max Revenue beat(2)5.6%
Revenue beat(4)2
Avg Revenue beat(4)-0.48%
Min Revenue beat(4)-6.61%
Max Revenue beat(4)5.6%
Revenue beat(8)3
Avg Revenue beat(8)-1.93%
Revenue beat(12)6
Avg Revenue beat(12)0.24%
Revenue beat(16)7
Avg Revenue beat(16)0.1%
PT rev (1m)0%
PT rev (3m)-0.23%
EPS NQ rev (1m)-0.65%
EPS NQ rev (3m)2.36%
EPS NY rev (1m)-14.05%
EPS NY rev (3m)-15.36%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)0.19%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)2.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.73
P/FCF N/A
P/OCF N/A
P/B 6.94
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.52
BVpS0.2
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.76%
ROE -856.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24%
FCFM N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
F-Score2
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 10.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.89%
Cap/Sales 4.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.92
Quick Ratio 6.02
Altman-Z -5.58
F-Score2
WACC6.55%
ROIC/WACCN/A
Cap/Depr(3y)69.29%
Cap/Depr(5y)60.46%
Cap/Sales(3y)7.21%
Cap/Sales(5y)5.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-52.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.13%
EPS Next Y-4.67%
EPS Next 2Y29.4%
EPS Next 3Y20.27%
EPS Next 5Y12.41%
Revenue 1Y (TTM)-17.35%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%10.42%
Revenue Next Year3.51%
Revenue Next 2Y9.4%
Revenue Next 3Y13.3%
Revenue Next 5Y14.38%
EBIT growth 1Y-77.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.57%
EBIT Next 3Y20.23%
EBIT Next 5Y15.78%
FCF growth 1Y42.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3YN/A
OCF growth 5YN/A